



Enhanced Protection, Continuous Improvement with Updated Flu Strains

Intervet's Influenza Vaccines Now Contain:

- Kentucky '93
- Kentucky '02
- Newmarket 2/93

Proven Protection & 6-Month DOI

Immunogenicity and Duration of Immunity (DOI) Study:

*Vaccinates: 18 seronegative, mixed sex, 6-month-old horses;
2 intramuscular doses of vaccine 3 weeks apart*

Controls: 7 similar horses served as non-vaccinated controls

At 6 months post-second vaccination, all horses were challenged intranasally with a live equine influenza virus. Post-challenge horses were observed for clinical signs of respiratory disease (pyrexia, coughing, nasal discharge, abnormal respiration, and depression), blood samples and nasal swabs were collected, and body temperatures were taken.

- Post-challenge, vaccinated horses showed a statistically significant reduction compared to controls in the following areas:
 - ~Body temperature
 - ~Clinical signs of respiratory disease
 - ~Virus shedding
- Study results demonstrate and support a 6-month DOI and following label claims:
 - ~Aid in prevention of respiratory disease caused by equine influenza
 - ~Aid in reduction in virus shedding of equine influenza

Proven Cross-Protection Against Ohio 03 and More

Serological Cross-Protection Study:

Serum samples from vaccinated horses used in the Immunogenicity and DOI study were tested for hemagglutination inhibition (HI) antibody levels to selected American and Eurasian strains of equine influenza viruses.

- Study results demonstrate and support the label claim:
 - ~Data suggest influenza cross-protection against certain North American and Eurasian strains including: KY91, KY93, KY99, KY02, OH03, Suffolk '89, Newmarket 1/93 and 2/93, and South Africa '03

Experts from the Office of International Epizootics and World Health Organization recommend updating equine influenza vaccines with new influenza strains to increase the relevance of vaccine strains to field strains.



Proven Safety: 99.4% Reaction-Free

Field Safety Trial Study Results:

Conducted by 6 veterinarians in 5 states; 552 healthy horses of various age, breed and sex, including 177 foals 4 months of age or younger

- 298 horses received 2 doses of vaccine; 254 horses received 1 dose of vaccine; 850 total doses
- All horses/foals were observed immediately and for 1, 2 or 3 days post-vaccination for signs of adverse reactions
- Proven safe in field safety trials: 99.4% reaction-free



Prestige® II with Havlogen®
Rhinopneumonitis – Influenza Vaccine
Killed Virus



Prestige® V with Havlogen®
Encephalomyelitis – Rhinopneumonitis – Influenza Vaccine
Eastern and Western, Killed Virus
Tetanus Toxoid



Prestige® V + VEE with Havlogen®
Encephalomyelitis – Rhinopneumonitis – Influenza Vaccine
Eastern, Western and Venezuelan, Killed Virus
Tetanus Toxoid



Encevac® TC-4 with Havlogen®
Encephalomyelitis – Influenza Vaccine
Eastern and Western, Killed Virus
Tetanus Toxoid



Encevac® TC-4 + VEE with Havlogen®
Encephalomyelitis – Influenza Vaccine
Eastern, Western and Venezuelan, Killed Virus
Tetanus Toxoid

Unique Havlogen Adjuvant

- Intervet's proprietary adjuvant technology
- Maintains uniform suspension for consistency and potency – doesn't settle out
- Stimulates both cell-mediated (T-cells) and humoral (B-cells) immune responses
- Produces a booster effect, stimulating higher, longer-lasting protection through the slow release of antigens

Recommend Intervet vaccines with updated flu strains.

Call your Intervet or distributor sales representative, or 1-800-441-8272, to order.

Prestige, Encevac and Havlogen are registered trademarks of Intervet Inc. or an affiliate. All rights reserved. 26780 Part # EQ-50323

29160 Intervet Lane
P.O. Box 318
Millsboro, Delaware 19966
www.intervetusa.com
800.441.8272



RESEARCH • PERFORMANCE • INTEGRITY